Strategies to Mitigate the Rising Cancer Cost Burden

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the increasing cost burden of cancer therapies and future strategies for mitigating costs.

Transcript

If you’re looking at it from a payer’s perspective, we see payers really paying a lot of attention to the oncology space, particularly self-administered oncology, looking at the criteria of use for those. You look at CML. Now we have patients who are living longer. This has become a chronic disease for these patients. So we see some specialty generics coming to space, imatinib for CML. You see some benefits across the entire space with overall cost of therapy with these specialty generics.